| Bioactivity | c-Myc inhibitor 15 (Compound A5) is a selective c-Myc inhibitor that exerts anticancer effects by disrupting the interaction between c-Myc and Max, leading to the degradation of c-Myc protein and the induction of apoptosis. Its IC50 values are 4.08 μM and 7.86 μM in A549 and NCI-H1299 lung cancer cell lines, respectively, demonstrating strong cytotoxic activity. In a syngeneic tumor model, c-Myc inhibitor 15 exhibited outstanding antitumor efficacy, achieving a tumor growth inhibition rate of 76.4% and significantly reducing c-Myc protein expression levels. c-Myc inhibitor 15 holds promise for research related to c-Myc-driven lung cancers[1]. |
| Formula | C27H31N5O2 |
| Molar Mass | 457.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gao J, et al. Discovery of 4-(4-(3-(1-(2-(piperidin-1-yl) ethyl)-1H-benzo [d] imidazole-2-yl) isoxazol-5-yl) phenyl) morpholine as a novel c-Myc inhibitor against lung cancer in vitro and in vivo[J]. European Journal of Medicinal Chemistry, 2025, 281: 117023. |